Top Qs
Timeline
Chat
Perspective

Mazdutide

GLP1 poly-agonist drug From Wikipedia, the free encyclopedia

Remove ads

Mazdutide (also known as IBI362 or LY3305677) is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).[1][2][3] The drug is developed by Eli Lilly and is currently in multiple Phase III studies.[4][5] In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.[6]

Quick Facts Clinical data, Other names ...

In June 2025, Mazdutide injection is approved for marketing in China.[7]

Remove ads

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads